Austin Neuromuscular Center is committed to research and clinical advancement. Our clinic is a site for clinical trials focusing mainly on neuromuscular disorders. Dr. Hussain is the principal investigator and we have on-site trained research coordinators.

Clinical Trials:

Pending

  • A Phase 3, 4-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure. – Pending
  • A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of APL-2 (Pegcetacoplan) in Subjects with Amyotrophic Lateral Sclerosis (ALS) – Pending
  • ARGX-113-1802: A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Pending

Active

  • A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS) – Active
  • Therapy in Amyotrophic Lateral Sclerosis (TAME) – Active
  • ALN-TTR02-012 “A Phase 4 Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients with Polyneuropathy of Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with a V122I or T60A Mutation” – Active
  • A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), 10% (GAMMAGARD LIQUID/KIOVIG) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) – Active
  • A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis. – Active
  • A Phase 3, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC with Standard Treatment Compared to Standard Treatment Alone in Improving Disease Activity in Adults with Active Idiopathic Inflammatory Myopathy (IIM). – Active
  • A Phase 2 Randomized, Double-blind, Placebo-controlled, Crossover Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients with Active Polymyositis or Dermatomyositis. – Active
  • A Open-label Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients with Generalized Myasthenia Gravis. – Active
  • A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects with Generalized Myasthenia Gravis. – Active
  • A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis. – Active
  • A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis. – Active
  • A Phase 2, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Patients With Generalized Myasthenia Gravis. – Active

Closed

  • A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intravenously Administered REGN2477+REGN1033 in Patients with Sporadic Inclusion Body Myositis. September 2018 – Closed
  • A Multicenter, Double Blind, Phase 2b, Placebo Controlled Study to assess the Efficacy and Safety of H.P. Acthar® Gel in the Treatment of Subjects with Amyotrophic Lather Sclerosis (ALS).
    June 2017 – Closed
  • Expanded Access Protocol of Patisiran for Patients with Hereditary Transthyretin-Mediated Amyloidosis (hATTR Amyloidosis) with Polyneuropathy.
    January 2017 – Closed
  • Patient Assisted Intervention for Neuropathy; Comparison of Treat in Real Life Situations (PAIN CONTROLS).
    October 2016 – Closed
  • Prospective, Double Blind, Randomized, Placebo Controlled, Phase III Study evaluating Efficacy and Safety of Octagam 10% in Patients with Dermatoymysitis. – Closed
  • A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults with Generalized Myasthenia Gravis. – Closed

For more information on clinical research studies, please visit the library for all research studies in the country.

For further questions regarding enrollment or study query please call our office directly 512-920-0140 and select option 6. You can also reach either of our research managers via email.
Nawar Hussin, MD – nawar@austinneuromuscle.com | Mary Trunk, RN, BSN – mary@austinneuromuscle.com